



## Y1 NEUROPEPTIDE Y RECEPTOR, HUMAN RECOMBINANT (Sf9)

Product Number **N 1399**

### Product Description

Y1 Neuropeptide Y (NPY-Y1) Receptor, human recombinant (Sf9) is a frozen aliquot of membranes from Sf9 cells transfected with the human recombinant Y1 neuropeptide Y receptor.

### Reagent

Y1 Neuropeptide Y Receptor, human recombinant (Sf9) is suspended at 2.0mg/mL in 50 mM Tris-HCl, pH 7.4, 10 % glycerol, and 1 % bovine serum albumin (BSA).

### Procedure

#### Incubation buffer:

50 mM Tris-HCl, pH 7.4  
120 mM NaCl  
5 mM KCl  
2 mM CaCl<sub>2</sub>  
1 mM MgCl<sub>2</sub>  
0.3 % BSA (add just before use)  
0.1 % Bacitracin

#### Binding Protocol

#### Membranes:

Dilute in incubation buffer (0.5 mL of membrane + 7.0 mL incubation buffer).

#### Assay mixture:

150 µl diluted membranes  
10 µl radioligand  
10 µl buffer or unlabeled ligand

#### Radioligand:

[<sup>125</sup>I] Peptide YY (porcine) at a final concentration of 0.14 nM for competition studies.

#### Unlabeled ligand:

BIBP3226 at a concentration of 1.0 µM

#### Incubation time:

60 minutes at 27 °C

## Product Information

### Separation:

Over GF/C filter (9 mm diam., presoaked in 0.3 % polyethylamine prepared in incubation buffer) then washed 9x with 200 µl of ice cold 50 mM Tris-HCl, pH 7.4 at 4 °C.

### Results

Typical affinities using standard binding assay above. Results may vary from lot to lot.

Ligand	K <sub>i</sub> (nM)
[ <sup>125</sup> I] Peptide YY (porcine)	0.14 (Kd)
Peptide YY	0.80
Peptide YY (Leu <sup>31</sup> , Pro <sup>34</sup> )	4.5
BIBP3226	7.8

### Storage/Stability

Store tightly sealed at -80 °C. Long term stability of this product is being evaluated. Initial studies indicate that the receptor can retain its original specific activity for several months when stored at -80 °C in its original packing solution. Repeated freeze-thaw of this product is not recommended.

### Precautions

While no human toxicity data is available for this substance, it should be handled with care. Precautions should be taken to avoid contact by all routes of exposure.

### References

1. Franco-Cereceda, A. and Liska, J., Eur. J. Pharmacol., **349**, 1-14 (1998).
2. Hoyle, C.H., Brain Res., **848**, 1-25 (1999).
3. Landry, M. et al., Exp. Neurol., **162**, 361-384 (2000).

mje 01/01

Sigma brand products are sold through Sigma-Aldrich, Inc.

Sigma-Aldrich, Inc. warrants that its products conform to the information contained in this and other Sigma-Aldrich publications. Purchaser must determine the suitability of the product(s) for their particular use. Additional terms and conditions may apply. Please see reverse side of the invoice or packing slip.